Email : info@otcjournal.com
URL : http://www.otcjournal.com
To
OTC Journal Members:
 |
ASTRALIS/ Hercules Development (OTC BB:
HDVG) APPOINTS DR. JAMES J. LEYDEN, MD, CHAIRMAN OF MEDICAL ADVISORY BOARD
|
|
Evidence is more compelling every
day that Astralis will indeed become the dream microcap investment
we originally anticipated. Today's announcement provides more evidence
that this wii be a major breakthrough for Psoriasis sufferers.
Dr. James Leyden, MD was appointed
head of the medical advisory board today. According to the press release,
Dr.
Leyden was instrumental in the development of Accutane, Bactroban,
Nizoral, Cleocin, Benzamycin, Benzaclin, and Minocin. Accutane is
the commercially successful and extremely expensive treatment for acne.
According to the press release, Dr.
Leyden has also served or is presently serving on the boards of many
of the nation’s key dermatological committees, including those of the American
Academy of Dermatology and the Dermatology Foundation. Dr. Leyden
has also served as a consultant to the US Food and Drug Administration
and the Federal Trade Commission, and to drug regulation agencies in England,
Germany and Austria.
It is becoming highly likely investors
will eventually make a substantial return on their investment dollar if
Psoraxine turns out to be a truly revolutionary new treatment for Psoriasis.
Today's news is another in a building
block in the ongoing process of bringing this revolutionary discovery to
the US market. For OTC Journal followers who were ignoring Energy
Power two weeks ago at $2.50, this is your wake up call.
One look at the picture provided
to us from the eight year Venezuelan study on Psoraxine should answer all
your questions. The potential market runs in the billions, and you have
the competitive edge with the infromation now.
Here is the complete text of the
news release for your review:
FOR IMMEDIATE RELEASE
ASTRALIS APPOINTS DR. JAMES
J. LEYDEN, MD, CHAIRMAN OF MEDICAL ADVISORY BOARD
Developer of ACCUTANE signs
contract with Astralis to oversee US clinical trials on PSORAXINE
FLORHAM PARK, NJ, October 15, 2001
– Hercules Development Group (OTC BB:HDVG) is pleased to announce that
Astralis, the company with which it has executed a definitive merger agreement,
has appointed Dr. James J. Leyden, MD as Chairman of the Company’s Medical
Advisory Board. In this role, Dr. Leyden will help coordinate clinical
trials on Psoraxine according to FDA guidelines. This appointment is effective
immediately.
Dr. Leyden is a Professor of Dermatology
at the Hospital of the University of Pennsylvania in Philadelphia. He has
served or is presently serving on the boards of many of the nation’s key
dermatological committees, including those of the American Academy of Dermatology
and the Dermatology Foundation. Dr. Leyden has also served as a consultant
to the US Food and Drug Administration and the Federal Trade Commission,
and to drug regulation agencies in England, Germany and Austria. Dr. Leyden
has also been instrumental in the development, testing and commercialization
of Accutane, Bactroban, Nizoral, Cleocin, Benzamycin, Benzaclin, Minocin
and the use of bicarbonate to control body odor.
“Dr. Leyden’s appointment as
Chairman of Astralis’s Medical Advisory Board is a significant development
for the Company,” said Mike Ajnsztajn, CEO of Astralis.
Astralis Chairman, Dr. Jose Antonio
O’Daly, MD, PhD commented: “With Dr. Leyden we have added a wealth of expertise
in the dermatological science industry. His reputation as a leading medical
professional in the field of dermatology means we will be able to enroll
the top doctors in the country as investigators for Psoraxine during its
clinical trials in the US.”
Dr. Leyden stated: “I have
the seen the results generated with Psoraxine on patients in Venezuela
over the past eight years, and I am looking forward to starting the American
clinical trials in the future.”
The first drug to be developed by
Astralis, PSORAXINE, has brought about clinical remission of the skin condition
known as Psoriasis during clinical trials conducted in Venezuela. The Company
has treated 3,000 patients with Psoraxine to-date. Of these, 638 experienced
complete remission and 1,000 have experienced between 70% and 90% remission.
The primary end point was the reduction of the Psoriasis Area and Severity
Index (PASI) before and after treatment with Psoraxine. Overall, 96% of
patients have responded positively to Psoraxine, with few adverse effects,
although these results were not independently verified.
Psoriasis affects 7 million
people in the United States alone, and conservative estimates indicate
that up to 3% of the world population also suffer from this condition—as
many as 180 million people. Psoriasis results due to an overproduction
of skin by blood cells associated with the immune system. These blood cells
become confused and act as though the skin was damaged, manufacturing skin
cells at a much faster rate than is required by undamaged skin. This overproduction
of skin can cause everything from itchy rash-like patches to painful pustules
and massive inflammation. Most current treatments are sub-optimal and some
systematic treatments can cause serious side effects. In fact, of the 7
million people living with Psoriasis in the US today, only 1.6 million
choose treatment.
Astralis is the developer of
Psoraxine, a drug that has brought about a clinical remission of the skin
condition Psoriasis in patient trials. The Company has applied for patent
protection for composition of matter, method of use, DNA sequence of peptides,
and the new gene sequence that fuels Psoraxine. The company is in the process
of submitting the IND for FDA approval to start US clinical trials
-30-
FOR MORE INFORMATION CONTACT:
The Investor Relations Group
Peter Waal
1-800-689-2966
|
Charts Provided Courtesy
Of TradePortal.com
The OTC Journal is
a proud partner of the SwingWire.com
Online Investment Community. A next generation Online Analyst Exchange
providing Members the ability to search, review, track and monitor some
of the Internet's best Online CAs (CyberAnalysts). Members
have the opportunity to potentially achieve higher
returns by viewing top performing portfolios
and receiving real-time alerts from favorite CAs.
SwingWire.com
also has a lucrative incentive model for experienced investors and traders
who consistently outperform the market. Share market ideas with other like-minded
investors, establish a proven track record, provide insightful commentary,
attract followers and ultimately become one of the Internet's highest paid
and most sought after CyberAnalysts!
Click
here to receive your FREE 30-Day Trial Membership with no further obligation.
Sign Up Today!
|
